First Generation pre|CISION^® Peptide Drug Conjugate: AVA6000

AVA6000 is our first generation pre|CISION^® peptide drug conjugate (PDC) which consists of doxorubicin conjugated directly with the pre|CISION^® peptide moiety, cleavable by fibroblast activation protein α (FAP). The peptide is cleaved in the TME to release active doxorubicin which is then capable of killing either FAP + cancer associated fibroblasts (CAFs) or FAP-negative tumor cells. These 1st Gen peptide drug conjugates are small molecules with advantages such as low costs of goods and a half-life in circulation measured in minutes to hours, suitable for cytotoxic payloads.

Fibroblast activation protein α (FAP) is an extracellular post-proline protease that is upregulated in many solid tumors in a membrane-bound form on cancer associated fibroblasts as well as tumour cells. FAP activity is also observed as a soluble protease to a low degree in plasma.